Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
46M
-
Shares change
-
+1.32M
-
Total reported value, excl. options
-
$406M
-
Value change
-
+$11.5M
-
Number of buys
-
38
-
Number of sells
-
-45
-
Price
-
$8.84
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2020
99 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2020.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46M shares
.
Largest 10 shareholders include ARK Investment Management LLC (11.2M shares), FMR LLC (6.63M shares), Sumitomo Mitsui Trust Holdings, Inc. (4.18M shares), Nikko Asset Management Americas, Inc. (4.18M shares), BlackRock Inc. (3.31M shares), Flagship Pioneering Inc. (2.94M shares), VANGUARD GROUP INC (2.03M shares), STATE STREET CORP (1.7M shares), Samsara BioCapital, LLC (1.41M shares), and JPMORGAN CHASE & CO (733K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.